Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

Finasteride treats hair loss but may affect prostate cancer detection.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

This study reported that molecules from Zebrafish embryo cell differentiation can counteract neurodegeneration, regenerate tissues, and potentially reverse hair follicle damage in androgenetic alopecia.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

CEC levels may be a useful marker for predicting prostate cancer progression.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

Gene variation affects prostate issues and hair loss.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

This study observed that frontal plus moderate vertex baldness at age 45 was associated with a higher risk of aggressive prostate cancer in a large cohort.

This study found that 5α-reductase inhibitors significantly reduced low-grade prostate cancer incidence in men but nearly doubled the incidence of high-grade prostate cancers.

This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

In this study, kolaviron and quercetin were found to reverse elevated biomarkers associated with testosterone-induced benign prostatic hyperplasia in Wistar rats, with both treatments effectively increasing HDL-c levels, though quercetin did not significantly affect triglyceride levels.